AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The study tests the safety and efficacy of axitinib in patients who have the hematologic
disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who
have poor prognosis before entering the study.